A Novo-funded Nordic study of 97,464 semaglutide users found no rise in pancreatic cancer, but follow-up lasted under two years after a lag.
Ozempic Users Worried About Pancreatic Cancer Get Reassuring Nordic Registry Data, but Follow-Up Lasted Under Two Years
by | Sep 30, 2026 | Uncategorized | 0 comments

Recent Comments